Principal Financial Group
RLMD icon

Principal Financial Group’s Relmada Therapeutics RLMD Stock Holding History

Principal Financial Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,870
Closed -$255K – 2526
2022
Q3 		$255K Buy
+6,870
New +$190K ﹤0.01% 2136

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Principal Financial Group's RLMD Position: Q4 2022 in Review

Principal Financial Group sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 6,870 shares — an estimated $255K sold.

Principal Financial Group first reported a position in RLMD in Q3 2022 and held it in 1 quarter. The position peaked at $255K in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

  • Principal Financial Group reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Principal Financial Group sold 6,870 Relmada Therapeutics shares in Q4 2022, an estimated $255K.
  • Principal Financial Group first reported a position in Relmada Therapeutics in Q3 2022 and held it in 1 quarter.
  • Principal Financial Group's Relmada Therapeutics position peaked at $255K in Q3 2022.
  • 110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Principal Financial Group's 13F filing for Q4 2022, filed 9 Feb 2023.